Cosmos Health shares rise 14.33% premarket after reporting 20% customer growth, improved unit economics, and $40M robotic revenue potential.

Cosmos Health Inc. surged 14.33% in premarket trading following the announcement of significant operational growth at its Greek pharmaceutical distribution subsidiary, Cosmofarm. The company reported a 20% increase in its active pharmacy customer base in 2025, alongside a 12% rise in revenue per customer and a 14% improvement in profitability per customer, driven by enhanced route density and operational efficiency. Additionally, Cosmofarm is expanding its robotic automation infrastructure with a $1 million investment, which management estimates could generate $40 million in incremental annual revenue. The CEO emphasized the strategic importance of these advancements in scaling capacity and supporting long-term value creation. While the release noted financial risks, the positive operational metrics and automation-driven growth projections appear to have driven the sharp premarket price increase.